ArticleJournal for immunotherapy of cancer2022
CD4
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
5.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 51 citations in OpenAlex.
- Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study.Signal transduction and targeted therapy · 2025Trial
- An immunogenomic classification of solid tumours reveals subtype-specific therapeutic vulnerabilities for immunotherapy.EBioMedicine · 2026Article
- Synthetic Biology Strategies for the Development of Live Attenuated Influenza Viruses: Recent Advances and Applications.Viruses · 2026Review
- Virus-like particles in cancer immunotherapy: bridging human and veterinary medicine through one health.Journal of nanobiotechnology · 2026Review
- Vaccination with cationic liposome-encapsulated CD4 and CD8 T cell neoepitopes induces superior tumor control.Materials today. Bio · 2026Article
- Prognostic value of systemic inflammation indices in patients with metastatic colorectal cancer treated with TAS-102: a single-center retrospective real-world study.Translational cancer research · 2026Article
- Immune Escape in Renal Cell Carcinoma: Latest Research and Treatment Strategies.International journal of molecular sciences · 2026Review
- Heterologous prime-boost immunization of AAV-based neoantigen cancer vaccine induces anti-tumor immunity to inhibit tumor growth and relapse.Cancer immunology, immunotherapy : CII · 2026Article
- DCC-2036 induces repolarization of TAMs to M1 type and enhances CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Chimeric MHC class I- and II-restricted non-self epitopes broaden antitumor T cell reactions.The Journal of experimental medicine · 2026Article
- Tumor-embedded Immunity and TRM Cell Functions in Cancer.Mini reviews in medicinal chemistry · 2026Review
- Article
- PD-1/PD-L1 pathway relieves incision induced acute postoperative pain via inhibiting the neuroinflammation in dorsal root ganglion of rats.Scientific reports · 2025Article
- Review
- Enhanced efficacy of immune checkpoint inhibitors with OK-432 in malignant pleural mesothelioma: A case report.Molecular and clinical oncology · 2025Article
- Immunoglobulin-like transcript 5 polarizes M2-like tumor-associated macrophages for immunosuppression in non-small cell lung cancer.International journal of cancer · 2025Article
- Synergistic Antitumor Effects of Caerin Peptides and Dendritic Cell Vaccines in a 4T-1 Murine Breast Cancer Model.Vaccines · 2025Article
- Targeting tumor metabolism to augment CD8Journal of pharmaceutical analysis · 2025Review
- Targeting DKK3 to remodel tumor immune microenvironment and enhance cancer immunotherapy.BMC cancer · 2025Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
25 authors at 8 institutions in 2 countries.
Minglu Xiao *Institute of Immunology, Third Military Medical University, Chongqing, China.
Luoyingzi Xie *Institute of Immunology, Third Military Medical University, Chongqing, China.
Guoshuai Cao *Pritzker School of Molecular Engineering, University of Chicago, Chicago, Illinois, USA.
Shun Lei *Institute of Immunology, Third Military Medical University, Chongqing, China.
Pengcheng WangKey Laboratory of Nephrology, Jinling Hospital National Clinical Research Center of Kidney Diseases, Nanjing, Jiangsu, China.
Zhengping WeiInstitute of Immunology, Third Military Medical University, Chongqing, China.
Yuan LuoDepartment of Immunology, Huazhong University of Science and Technology Tongji Medical College School of Basic Medicine, Wuhan, Hubei, China.
Jingyi FangInstitute of Immunology, Third Military Medical University, Chongqing, China.
Xingxing YangInstitute of Cancer, Third Military Medical University Second Affiliated Hospital, Chongqing, China.
Qizhao HuangSchool of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, China.
Lifan XuInstitute of Immunology, Third Military Medical University, Chongqing, China.
Junyi GuoGuangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Stomatological Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Shuqiong WenGuangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Stomatological Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Zhiming WangInstitute of Immunology, Third Military Medical University, Chongqing, China.
Qing WuInstitute of Immunology, Third Military Medical University, Chongqing, China.
Jianfang TangInstitute of Immunology, Third Military Medical University, Chongqing, China.
Lisha WangInstitute of Immunology, Third Military Medical University, Chongqing, China.
Xiangyu ChenSchool of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, China.
Cheng ChenInstitute of Immunology, Third Military Medical University, Chongqing, China.
Yanyan ZhangInstitute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, University of Chinese Academy of Sciences, Chongqing, China.
Wei YaoInstitute of Immunology, Third Military Medical University, Chongqing, China.
Jianqiang YeKey Laboratory of Jiangsu Preventive Veterinary Medicine, Key Laboratory for Avian Preventive Medicine, Ministry of Education, College of Veterinary Medicine, Yangzhou University, Yangzhou, Jiangsu, China yelilinlcmv@163.com huangjun@uchicago.edu ranhe@hust.edu.cn jqye@yzu.edu.cn.
Ran HeDepartment of Immunology, Huazhong University of Science and Technology Tongji Medical College School of Basic Medicine, Wuhan, Hubei, China yelilinlcmv@163.com huangjun@uchicago.edu ranhe@hust.edu.cn jqye@yzu.edu.cn.
Jun HuangPritzker School of Molecular Engineering, University of Chicago, Chicago, Illinois, USA yelilinlcmv@163.com huangjun@uchicago.edu ranhe@hust.edu.cn jqye@yzu.edu.cn.ORCID 0000-0003-0271-4384
Lilin YeInstitute of Immunology, Third Military Medical University, Chongqing, China yelilinlcmv@163.com huangjun@uchicago.edu ranhe@hust.edu.cn jqye@yzu.edu.cn.ORCID 0000-0003-0778-3311
Army Medical University · CNHuazhong University of Science and Technology · CNSouthern Medical University · CNStomatology Hospital · CNUniversity of Chicago · USNanjing General Hospital of Nanjing Military Command · CNUniversity of Chinese Academy of Sciences · CNYangzhou University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntitumor therapeutic vaccines are generally based on antigenic epitopes presented by major histocompatibility complex (MHC-I) molecules to induce tumor-specific CD8
methods
resultsCD4
conclusionCD4
Indexed as
AdenocarcinomaColorectal NeoplasmsMelanomaAnimalsB7-H1 AntigenCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesEpitopes, T-LymphocyteGlycoproteinsHumansImmune Checkpoint InhibitorsImmunotherapyMiceOvalbuminProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellB7-H1 AntigenEpitopes, T-LymphocyteGlycoproteinsImmune Checkpoint InhibitorsOvalbuminProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesImmunizationImmunotherapyVaccination
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.